Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:27 2025-06-20 am EDT			5-day change	1st Jan Change
259.30 ^CHF	-0.27%		-3.86%	+1.49%

01:41am	Roche's Investigational Therapy for Lymphoma Demonstrates 'Significant' Improvement	MT
Jun. 20	Roche's Lymphoma Treatment Shows Promise in Late-Stage Trial	DJ

ROCHE HOLDING : 2025 starts with a beat; tariff-led correction an entry opportunity

Published on 04/24/2025 at 07:26, updated on 04/24/2025 at 08:00

This Alphavalue article, the European leader in independent research, is only available to subscribers .

Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Roche Holding AG

Roche's Investigational Therapy for Lymphoma Demonstrates 'Significant' Improvement	01:41am	MT
Roche's Lymphoma Treatment Shows Promise in Late-Stage Trial	Jun. 20	DJ
Obesity: preserving muscle, the new challenge	Jun. 19
Swiss trade surplus at CHF 3.831 bln in May	Jun. 19	RE
Fat, not muscle: Drugmakers in race for next weight-loss breakthrough	Jun. 18	RE
Maia Biotechnology Signs Clinical Supply Deal With Roche; Shares Rise	Jun. 18	MT
MAIA Biotechnology, Inc. Announces Master Clinical Supply Agreement with Roche for Hard-To-Treat Cancer Therapies	Jun. 18	CI
Fat, not muscle: Drugmakers in race for next weight-loss breakthrough	Jun. 18	RE
ROCHE HOLDINGS AG : Sell rating from Deutsche Bank	Jun. 17	ZD
Swiss stocks - Factors to watch on June 17	Jun. 17	RE
Sarepta shares crash as second patient dies after receiving its gene therapy	Jun. 16	RE
ROCHE HOLDINGS AG : Gets a Buy rating from UBS	Jun. 16	ZD
Swiss Stocks Kick Off New Trading Week Downbeat Amid Gloomy Economic Forecasts	Jun. 16	MT
Analyst recommendations: Meta, Eli Lilly, RTX Corp, Airbus, Roche…	Jun. 16
AbbVie says blood cancer drug fails late-stage trial	Jun. 16	RE
Upcoming Fed Meeting Eyed as US Equity Futures Rise Pre-Bell	Jun. 16	MT
North American Morning Briefing : Stock Futures Rise As Israel-Iran Conflict Enters Fourth Day	Jun. 16	DJ
Prothena's Partner to Advance Potential Parkinson's Treatment to Phase 3 Development	Jun. 16	MT
Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures	Jun. 16	DJ
Roche: moving towards phase 3 in Parkinson's disease	Jun. 16	CF
Roche to Advance Prasinezumab Into Phase 3 Trial for Early-Stage Parkinson's Disease	Jun. 16	DJ
Roche to Proceed with Phase Three Development of Investigational Drug for Parkinson's Disease	Jun. 16	MT
Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease	Jun. 16	CI
Roche To Advance Prasinezumab Into Phase III Development For Early-Stage Parkinson's Disease	Jun. 16	RE
Swiss stocks - Factors to watch on June 16	Jun. 16	RE

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,249

Sector

Pharmaceuticals

Calendar

Jun. 23 - Investor Meeting

More about the company